Physician profile
Victor E Ylagan
NPI 1265464945
$19,375.90
in general payments reported to CMS, 2019-2025
65 companies · $3,382 in 2025
The $3,382 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,072 · 2020: $1,747 · 2021: $1,739 · 2022: $3,093 · 2023: $2,589 · 2024: $3,754 · 2025: $3,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,650 · Education: $75.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,649.76 |
| Education | $75.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,065.67 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Emd Serono, INC. | $1,738.85 | 2019-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $1,407.40 | 2020-2025 | Xcopri |
| Biogen, INC. | $1,213.98 | 2019-2024 | Vumerity, Tysabri |
| Amgen INC. | $1,000.41 | 2019-2025 | Uplizna, Aimovig |
| Ucb, INC. | $650.39 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $603.12 | 2019-2024 | Ingrezza, Ongentys |
| Lilly USA, LLC | $597.80 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $560.12 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Teva Pharmaceuticals USA, INC. | $558.45 | 2019-2023 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $554.48 | 2019-2025 | |
| Lundbeck LLC | $444.59 | 2020-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $436.33 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $401.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Pfizer INC. | $390.92 | 2023-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Ylagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.